In this study, researchers utilized a synthetic peptide to bind and inhibit the claudin-1 protein. Claudin-1 protein is essential for skin barrier strength and decreases the permeability of the skin. It is noted that eczema patients have significantly reduced claudin-1 and therefore has leaky skin barrier.
Researchers utilized synthetic peptide to inhibit claudin-1 along with recombinant flu vaccine to create a patch. Testing on mice researchers found that in previously immunized mice it elicited a significant immune reaction. Further testing showed no lasting damage to the skin at the site of the patch.
Although it is still in the early stages of development, this study shows potential for needle-free vaccine patch development. Needle-free vaccines have great potential as they reduce the burden on health care professionals, reduces biowaste hazard and generally appealing for people as there is no injection involved.